Effectiveness of nivolumab in second-line and later in patients with advanced non-small cell lung cancer in real-life practice in france and germany: analysis of the esme-amlc and crisp cohorts

HIGHLIGHTS

• who: Christos Chouaid et al. from the Cancer in Real-Life Practice in France Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Ru00f6ntgenstr, have published the Article: Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts, in the Journal: Cancers 2022, 14, x FOR PEER REVIEW of 13/Dec/2022
• what: This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.